Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ra Pharmaceuticals Inc (RARX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 658,692
  • Shares Outstanding, K 32,398
  • Annual Sales, $ 0 K
  • Annual Income, $ -54,440 K
  • 36-Month Beta 0.90
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.52
  • Number of Estimates 4
  • High Estimate -0.47
  • Low Estimate -0.55
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +22.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.35 +9.26%
on 02/07/19
22.25 -9.89%
on 02/04/19
+0.44 (+2.24%)
since 01/15/19
3-Month
13.73 +46.03%
on 11/21/18
23.90 -16.11%
on 01/08/19
+5.38 (+36.67%)
since 11/15/18
52-Week
4.78 +319.46%
on 04/04/18
23.90 -16.11%
on 01/08/19
+13.26 (+195.29%)
since 02/15/18

Most Recent Stories

More News
Ra Pharmaceuticals Announces Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis

--Clinically meaningful and statistically significant reductions in both QMG and MG-ADL

RARX : 20.05 (-1.38%)
Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that it has received a development milestone payment under its collaboration agreement with Merck, known as MSD outside the US and Canada....

RARX : 20.05 (-1.38%)
MRK : 79.81 (+1.10%)
Ra Pharmaceuticals Elects Bo Cumbo to Board of Directors

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the election of Bo Cumbo to its board of directors. Mr. Cumbo is a veteran of the biotechnology industry and has played strategically...

RARX : 20.05 (-1.38%)
SRPT : 138.45 (+2.65%)
ADDING and REPLACING Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

--On track for topline data read-out around year-end 2018

RARX : 20.05 (-1.38%)
SYBX : 9.29 (+3.80%)
Ra Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

--On track for topline data read-out around year-end 2018

RARX : 20.05 (-1.38%)
SYBX : 9.29 (+3.80%)
Ra Pharmaceuticals to Present at Upcoming Investor Conferences

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that senior management will present at the following upcoming investor conferences:

RARX : 20.05 (-1.38%)
Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that data from the Company's oral, small molecule, complement C5 inhibitor program and data from the Company's global, Phase 2 clinical...

RARX : 20.05 (-1.38%)
Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced financial results for the first quarter ended March 31, 2018 and provided an update on recent corporate and clinical developments.

RARX : 20.05 (-1.38%)
Ra Pharmaceuticals Announces Presentation of RA101495 SC Phase 2 gMG Clinical Trial Design at the 70th Annual AAN Meeting

Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that the design of its Phase 2 clinical trial of RA101495 SC as a treatment for generalized myasthenia gravis (gMG) will be presented...

RARX : 20.05 (-1.38%)
Ra Pharmaceuticals Appoints John C. King as Chief Commercial Officer

Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases,...

RARX : 20.05 (-1.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade RARX with:

Business Summary

Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 20.78
1st Resistance Point 20.41
Last Price 20.05
1st Support Level 19.62
2nd Support Level 19.20

See More

52-Week High 23.90
Last Price 20.05
Fibonacci 61.8% 16.60
Fibonacci 50% 14.34
Fibonacci 38.2% 12.08
52-Week Low 4.78

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar